<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">93750</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Nekotorye aspekty kardiovaskulyarnoy bezopasnosti tiotropiya u bol'nykh khronicheskoy obstruktivnoy bolezn'yu legkikh i ishemicheskoy bolezn'yu serdtsa</article-title><trans-title-group xml:lang="ru"><trans-title>Некоторые аспекты кардиоваскулярной безопасности тиотропия у больных хронической обструктивной болезнью легких и ишемической болезнью сердца</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Karoli</surname><given-names>N. A</given-names></name><name xml:lang="ru"><surname>Кароли</surname><given-names>Н. А</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра госпитальной терапии лечебного факультета</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rebrov</surname><given-names>A. P</given-names></name><name xml:lang="ru"><surname>Ребров</surname><given-names>А. П</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра госпитальной терапии лечебного факультета</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ГБОУ ВПО Саратовский ГМУ им. В.И.Разумовского Минздрава РФ</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2013-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2013</year></pub-date><volume>15</volume><issue>3</issue><issue-title xml:lang="en">VOL 15, NO3 (2013)</issue-title><issue-title xml:lang="ru">ТОМ 15, №3 (2013)</issue-title><fpage>24</fpage><lpage>28</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2013, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2013, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2013</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/93750">https://consilium.orscience.ru/2075-1753/article/view/93750</self-uri><abstract xml:lang="ru"><p>За последние десятилетия отмечается рост заболеваемости и смертности от хронической обструктивной болезни легких (ХОБЛ) в большинстве стран мира. Если в 1990 г. ХОБЛ занимала 6-е место среди причин смерти, в 2000 г. – 4-е, то к 2020 г. ожидается, что ХОБЛ будет находиться на 3-м месте среди основных причин смерти. В настоящее время достигнуты значительные успехи как в понимании патогенеза воспалительных изменений в дыхательных путях, так и в лечении ХОБЛ. Несмотря на это, доля ХОБЛ в общей структуре заболеваемости и смертности неуклонно увеличивается. ХОБЛ занимает 3-е место среди причин смертности в возрастной группе старше 50 лет. Эта категория пациентов характеризуется полиморбидностью, которая является особенностью современной клиники внутренних болезней, а ишемическая болезнь сердца (ИБС), артериальная гипертензия (АГ) и ХОБЛ остаются наиболее распространенными заболеваниями взрослого населения развитых стран.</p></abstract><kwd-group xml:lang="ru"><kwd>хроническая обструктивная болезнь легких</kwd><kwd>ишемическая болезнь сердца</kwd><kwd>тиотропия бромид</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии. Рациональная фармакотерапия в кардиологии. 2009; 4: 9–17.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Anthonisen N.R., Connet J.E., Enright P.L., Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333–9.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Sidney S, Sorel M, Quesenberry C.P. et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068–75.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567–72.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Sin D.D., Man S.F.P. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8–11.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Peters N.L. Snipping the thread of life. Antimuscarinic side effects of medications in the elderly. Arch Int Med 1989; 149: 2414e20.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3: 335e48.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Worth H, Chung K.F., Felser J.M. et al. Cardio - and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105 (4): 571–9.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lee T.A., Simon A, Pickard A.S. et al. Risk of death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380–90.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Singh S, Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. J Am Med Assoc 2008; 300: 1439–50.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Singh S, Loke Y.K., Enright P, Furberg CD. Pro - arrhythmic and pro - ischaemic effects of inhaled anticholinergic medications. Thorax 2013; 68 (1): 114–6.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Cazzola M, Calzetta L, Matera M.G. The cardiovascular risk of tiotropium: is it real? Expert Opin Drug Saf 2010; 9: 783–92.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Tashkin D.P., Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–54.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364 (12): 1093–103.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Rodrigo G.J., Castro-Rodriguez J.A., Nannini L.J. et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta - analysis. Respir Med 2009; 103 (10): 1421–9.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kesten S, Jara M, Wentworth C, Lanes S et al. Pooled Clinical Trial Analysis of Tiotropium Safety. Chest December 2006; 130: 1695–703.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kesten S, Celli B, Decramer M et al. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis 2009; 4: 397–409.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Celli B, Decramer M, Leimer I et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137 (1): 20–30.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Gershon A.S., Wang L, To T et al. Survival with tiotropium compared to long - acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease. COPD 2008; 5 (4): 229–34.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>De Luise C, Lanes S.F., Jacobsen J et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007; 22: 267–72.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Verhamme K.M., Afonso A.S., van Noord C et al. Tiotropium Handihaler and the risk of cardio - or cerebrovascular events and mortality in patients with COPD. Pulm Pharmacol Ther 2012; 25 (1): 19–26.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Jara M, Lanes S.F., Wentworth C et al. Comparative safety of long - acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007; 30: 1151–60.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Short P.M., Williamson P.A., Elder D.H. et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long - acting beta - agonist therapy in COPD. Chest 2012; 141: 81–6.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Lee T.A., Wilke C, Joo M et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009; 169 (15): 1403–10.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Jara M, Wentworth C, Lanes S. A new user cohort study comparing the safety of long - acting inhaled bronchodilators in COPD. BMJ Open 2012; 2 (3).</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>FDA (US) (2009) UCM190463. Available at: http://www.fda. gov/ downloads/advisorycommittees/committeesmeetingmaterials/drugs/pulmonary allergydrug sadvisorycommittee/ ucm190463.pdf (accessed 14 October 2011).</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Santus P, Di Marco F, Radovanovic D, Centanni S. Tiotropium: what came after the UPLIFT study. Expert Opin Pharmacother 2012; 13: 613–8.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Singh S, Loke Y.K., Enrigh P.L., Furberg C.D. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta - analysis of randomised controlled trials. BMJ 2011; 342: d3215.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Dong Y.H., Lin H.H., Shau W.Y. et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta - analysis of randomised controlled trials. Thorax 2013; 68 (1): 48–56.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ichinose M, Fujimoto T, Fukuchi Y. Tiotropium 5 mg via Respimat and 18 mg via HandiHaler; efficacy and safety in Japanese COPD patients. Respir Med 2010; 104: 228–36.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>http://www.clinicaltrials.gov/ct2/show/NCT01222533? term=205.458&amp;rank=1 (accessed 4 Feb 2013).</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Metzdorf N, Hallmann C, Disse B. Thorax editorial by Jenkins and Beasley related to tiotropium respimat. Thorax published online February 12, 2013. doi: 10.1136/thoraxjnl-2013-203228.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Oba Y, Zaza T, Thameem D.M. Safety, tolerability and risk benefit analysis of tiotropium in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3 (4): 575–84. Review.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Loke Y.K., Singh S. Risks Associated With Tiotropium in Chronic Obstructive Pulmonary Disease. Overview of the Evidence to Date. Ther Adv in Drug Safe 2012; 3 (3): 123–31.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Lelorier J, Gregoire G, Benhaddad A et al. (1997) Discrepancies between meta - analyses and subsequent large randomized, controlled trials. N Engl J Med 337: 536–42.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Horwitz R.I., Singer B.H., Makuch R.W., Viscoli C.M. Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulation. J Clin Epidemiol 1996; 49: 395–400.</mixed-citation></ref></ref-list></back></article>
